The Fetal Safety of Fluoxetine: A Systematic Review and Meta-Analysis

Journal of Obstetrics and Gynaecology Canada

Volumn 35, Issue 4, 2013, Pages 362-369

  Riggin, Lauren ^a   Frankel, Zipora ^a   Moretti, Myla ^a   Pupco, Anna ^a   Koren, Gideon ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Fluoxetine; Malformations; Meta analysis; Pregnancy; Selective serotonin reuptake inhibitor; SSRIs

Indexed keywords

FLUOXETINE; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; COHORT ANALYSIS; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; DRUG USE; FETUS; FIRST TRIMESTER PREGNANCY; HUMAN; META ANALYSIS; PRENATAL DRUG EXPOSURE; PUERPERAL DEPRESSION; RISK FACTOR; SYSTEMATIC REVIEW; TERATOGENICITY; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; CONGENITAL MALFORMATION; DEPRESSION; FEMALE; MALFORMATIONS; MEDLINE; PREGNANCY; PREGNANCY COMPLICATION; PSYCHOLOGICAL ASPECT; REVIEW; RISK; SSRIS;

FLUOXETINE; MALFORMATIONS; META-ANALYSIS; PREGNANCY; SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SSRIS;

ABNORMALITIES, DRUG-INDUCED; CASE-CONTROL STUDIES; COHORT STUDIES; DEPRESSION; FEMALE; FLUOXETINE; HEART DEFECTS, CONGENITAL; HUMANS; MEDLINE; ODDS RATIO; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; SEROTONIN UPTAKE INHIBITORS;

MLCS; MLOWN;

EID: 84879539214     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30965-8     Document Type: Article

References (59)

1. Kessler R.C. Epidemiology of women and depression. J Affect Disord 2003, 74:5-13.
2. Dietz P.M., Williams S.B., Callaghan W.M., Bachman D.J., Whitlock E.P., Hornbrook M.C. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry 2007, 164:1515-1520. doi: 10.1176/appi.ajp.2007.06111893.
3. Bennett H.A., Einarson A., Taddio A., Koren G., Einarson T.R. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004, 103:698-709. doi: 10.1097/01.AOG.0000116689.75396.5f.
4. Cohen L.S., Altshuler L.L., Harlow B.L., Nonacs R., Newport D.J., Viguera A.C., et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006, 295:499-507. doi: 10.1001/jama.295.5.499.
5. Einarson A., Selby P., Koren G. Discontinuing antidepressants and benzodiazepines upon becoming pregnant. Beware of the risks of abrupt discontinuation. Can Fam Physician 2001, 47:489-490.
6. Zuckerman B., Amaro H., Bauchner H., Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989, 160(5 Pt 1):1107-1111.
7. Wisner K.L., Zarin D.A., Holmboe E.S., Appelbaum P.S., Gelenberg A.J., Leonard H.L., et al. Risk-benefit decision making for treatment of depression during pregnancy. Am J Psychiatry 2000, 157:1933-1940.
8. Vintzileos A., Ananth C.V., Smulian J.C., Scorza W.E., Knuppel R.A. The impact of prenatal care on postneonatal deaths in the presence and absence of antenatal high-risk conditions. Am J Obstet Gynecol 2002, 187:1258-1262.
9. Kogan M.D., Alexander G.R., Jack B.W., Allen M.C. The association between adequacy of prenatal care utilization and subsequent pediatric care utilization in the United States. Pediatrics 1998, 102(1 Pt 1):25-30.
10. Kelly R.H., Danielsen B.H., Golding J.M., Anders T.F., Gilbert W.M., Zatzick D.F. Adequacy of prenatal care among women with psychiatric diagnoses giving birth in California in 1994 and 1995. Psychiatr Serv 1999, 50:1584-1590.
11. Paarlberg K.M., Vingerhoets A.J., Passchier J., Dekker G.A., Van Geijn H.P. Psychosocial factors and pregnancy outcome: a review with emphasis on methodological issues. J Psychosom Res 1995, 39:563-595.
12. McFarland J., Salisbury A.L., Battle C.L., Hawes K., Halloran K., Lester B.M. Major depressive disorder during pregnancy and emotional attachment to the fetus. Arch Womens Ment Health 2011, 14:425-434. doi: 10.1007/s00737-011-0237-z; 10.1007/s00737-011-0237-z.
13. Belik J. Fetal and neonatal effects of maternal drug treatment for depression. Semin Perinatol 2008, 32:350-354. doi: 10.1053/j.semperi.2008.08.001.
14. Sadler T.W. Selective serotonin reuptake inhibitors (SSRIs) and heart defects: potential mechanisms for the observed associations. Reprod Toxicol 2011, 32:484-489. doi: 10.1016/j.reprotox.2011.09.004.
15. Malm H., Artama M., Gissler M., Ritvanen A. Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011, 118:111-120. doi: 10.1097/AOG.0b013e318220edcc.
16. Malm H., Klaukka T., Neuvonen P.J. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005, 106:1289-1296. doi: 10.1097/01.AOG.0000187302.61812.53.
17. Ellfolk M., Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs). Reprod Toxicol 2010, 30:249-260. doi: 10.1016/j.reprotox.2010.04.015.
18. Addis A., Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000, 30:89-94.
19. Tuccori M., Montagnani S., Testi A., Ruggiero E., Mantarro S., Scollo C., et al. Use of selective serotonin reuptake inhibitors during pregnancy and risk of major and cardiovascular malformations: an update. Postgrad Med 2010, 122(4):49-65. doi: 10.3810/pgm.2010.07.2175.
20. Tuccori M., Testi A., Antonioli L., Ruggiero E., Mantarro S., Scollo C., et al. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009, 31(Pt 1):1426-1453. doi: 10.1016/j.clinthera.2009.07.009.
21. Ericson A., Kallen B., Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Clin Pharmacol 1999, 55:503-508.
22. Hendrick V., Smith L.M., Suri R., Hwang S., Haynes D., Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003, 188:812-815.
23. Goldstein D.J., Corbin L.A., Sundell K.L. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997, 89(5 Pt 1):713-718.
24. Wisner K.L., Sit D.K., Hanusa B.H., Moses-Kolko E.L., Bogen D.L., Hunker D.F., et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009, 166:557-566. doi: 10.1176/appi.ajp.2008.08081170.
25. Nulman I., Rovet J., Stewart D.E., Wolpin J., Gardner H.A., Theis J.G., et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997, 336(4):258-262. doi: 10.1056/NEJM199701233360404.
26. Nulman I., Rovet J., Stewart D.E., Wolpin J., Pace-Asciak P., Shuhaiber S., et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002, 159:1889-1895.
27. Suri R., Altshuler L., Hendrick V., Rasgon N., Lee E., Mintz J. The impact of depression and fluoxetine treatment on obstetrical outcome. Arch Womens Ment Health 2004, 7:193-200. doi: 10.1007/s00737-004-0057-5.
28. Lund N., Pedersen L.H., Henriksen T.B. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009, 163:949. 4, doi: 10.1001/archpediatrics.2009.164.
29. Cohen L.S., Heller V.L., Bailey J.W., Grush L., Ablon J.S., Bouffard S.M. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000, 48:996-1000.
30. Simon G.E., Cunningham M.L., Davis R.L. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002, 159:2055-2061.
31. Pearson K.H., Nonacs R.M., Viguera A.C., Heller V.L., Petrillo L.F., Brandes M., et al. Birth outcomes following prenatal exposure to antidepressants. J Clin Psychiatry 2007, 68:1284-1289.
32. Davis R.L., Rubanowice D., McPhillips H., Raebel M.A., Andrade S.E., Smith D., et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007, 16:1086-1094. doi: 10.1002/pds.1462.
33. Wichman C.L., Moore K.M., Lang T.R., St.Sauver J.L., Heise R.H., Watson W.J. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clin Proc 2009, 84:23-27.
34. Hallberg P., Sjoblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. J Clin Psychopharmacol 2005, 25:59-73.
35. Casper R.C., Fleisher B.E., Lee-Ancajas J.C., Gilles A., Gaylor E., DeBattista A., et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003, 142:402-408. doi: 10.1067/mpd.2003.139.
36. Wogelius P., Nørgaard M., Gislum M., Pedersen L., Munk E., Mortensen P.B., et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006, 17:701-704. doi: 10.1097/01.ede.0000239581.76793.ae.
37. Nijenhuis C.M., ter Horst P.G., van Rein N., Wilffert B., de Jong-van den Berg L.T. Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 2: testing the hypotheses. Br J Clin Pharmacol 2012, 73:126-134. doi: 10.1111/j.1365-2125.2011.04081.x; 10.1111/j.1365-2125.2011.04081.x.
38. Pedersen L.H., Henriksen T.B., Vestergaard M., Olsen J., Bech B.H. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009, 339:b3569. doi: 10.1136/bmj.b3569.
39. Diav-Citrin O., Shechtman S., Weinbaum D., Wajnberg R., Avgil M., Di Gianantonio E., et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008, 66:695-705. doi: 10.1111/j.1365-2125.2008.03261.x.
40. Einarson A., Choi J., Einarson T.R., Koren G. Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study. Can J Psychiatry 2009, 54:242-246.
41. Reis M., Kallen B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010, 40:1723-1733. doi: 10.1017/S0033291709992194.
42. Oberlander T.F., Warburton W., Misri S., Riggs W., Aghajanian J., Hertzman C. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008, 83:68-76. doi: 10.1002/bdrb.20144.
43. Kallen B.A., Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007, 79:301-308. doi: 10.1002/bdra.20327.
44. GlaxosmithKline. Clinical study register. Preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformation 2012, Available at:, Accessed August 23. http://download.gsk-clinicalstudyregister.com/files/28398.pdf.
45. Goldstein D.J., Sundell K.L., Corbin L.A. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1997, 336:872-873. author reply 873.
46. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335(14):1010-1015. doi: 10.1056/NEJM199610033351402.
47. Nordeng H., van Gelder M.M., Spigset O., Koren G., Einarson A., Eberhard-Gran M. Pregnancy outcome after exposure to antidepressants and the role of maternal depression: results from the Norwegian mother and child cohort study. J Clin Psychopharmacol 2012, 32:186-194. doi: 10.1097/JCP.0b013e3182490eaf.
48. Kornum J.B., Nielsen R.B., Pedersen L., Mortensen P.B., Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clin Epidemiol 2010, 2:29-36.
49. Colvin L., Slack-Smith L., Stanley F.J., Bower C. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy. Birth Defects Res A Clin Mol Teratol 2011, 91:142-152. doi: 10.1002/bdra.20773; 10.1002/bdra.20773.
50. McElhatton P.R., Garbis H.M., Elefant E., Bellemin B., Mastroiacovo P., Arnon J., et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European network of teratology information services (ENTIS). Reprod Toxicol 1996, 10:285-294.
51. Merlob P., Birk E., Sirota L., Linder N., Berant M., Stahl B., et al. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 2009, 85:837-841. doi: 10.1002/bdra.20615.
52. Jimenez-Solem E., Andersen J.T., Petersen M., Broedbaek K., Jensen J.K., Afzal S., et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012, 2(3). pii: e001148.10.1136/bmjopen-2012-001148. Print 2012.
53. Pastuszak A., Schick-Boschetto B., Zuber C., Feldkamp M., Pinelli M., Sihn S., et al. Pregnancy outcome following first-trimester exposure to fluoxetine (prozac). JAMA 1993, 269:2246-2248.
54. Bakker M.K., De Walle H.E., Wilffert B., de Jong-Van den Berg L.T. Fluoxetine and infantile hypertrophic pylorus stenosis: a signal from a birth defects-drug exposure surveillance study. Pharmacoepidemiol Drug Saf 2010, 19:808-813. doi: 10.1002/pds.1964.
55. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., Friedman J.M. National Birth Defects Prevention Study. Use of selective serotoninreuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007, 356:2684-2692. doi: 10.1056/NEJMoa066584.
56. Louik C., Lin A.E., Werler M.M., Hernandez-Diaz S., Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007, 356:2675-2683. doi: 10.1056/NEJMoa067407.
57. Maxson P., Miranda M.L. Pregnancy intention, demographic differences, and psychosocial health. J Womens Health (Larchmt) 2011, 20:1215-1223. doi: 10.1089/jwh.2010.2379.
58. Koren G., Pastuszak A.P. Ito S: Drugs in pregnancy. N Eng J Med 1998, 338(16):1128-1137.
59. Bar-Oz B., Einarson T., Einarson A., Boskovic R., O'Brien L., Malm H., et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors. Clin Ther 2007, 29:918-926.